MYCN reporter gene assay will be scaled up for high throughput screens of compound libraries and will aid in the future development of specific therapeutic strategies in neuroblastoma and other tumours (Papadopoulos et al., 2022; Lu et al., 2003). This evidence concerns the gene MYCN and neuroblastoma.